Post-earnings recap
Reported
Fri, Jul 31, 2026
EPS actual
$3.65
EPS est.
$3.64
EPS surprise
+0.39%
1-day move
-2.51%
AbbVie reported better-than-expected earnings per share, which indicates some operational strength. However, the stock fell by 2.51% following the earnings report, likely due to the lack of revenue information and guidance. Investors may be cautious without further insights from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.65 | $3.61 | +0.39% |
| Revenue | N/A | $16.8B | N/A |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
AbbVie Inc. is a global biopharmaceutical company focused on developing advanced therapies for complex health conditions. With a market cap of $443 billion, AbbVie plays a significant role in the healthcare sector, particularly in biotechnology, addressing major themes like chronic diseases and immunology.
Last quarter
In Q1 2026, AbbVie reported an EPS of $2.65, slightly beating expectations. The stock reacted positively, gaining 3.14% the following day.
Management promises and guidance
EPS beat streak
4Q
EPS beat rate
88%
Avg EPS surprise
+0.89%
Avg 1-day reaction
+0.81%
Analysts are generally optimistic about AbbVie's upcoming earnings, expecting solid EPS and revenue growth. The company has a strong track record of beating earnings estimates.
Bull case
If AbbVie exceeds the EPS estimate and shows strong revenue growth, it could reinforce investor confidence and lead to a significant stock price increase.
Bear case
Conversely, if AbbVie misses earnings expectations or provides weak guidance, it could raise concerns about its growth trajectory and negatively impact the stock.
Key metrics to watch
EPS
$3.61Earnings per share (EPS) is a key indicator of profitability and will show how well AbbVie is managing its costs and revenues.
Revenue
$16.8BTotal revenue reflects the company's sales performance and market demand for its products, which is crucial for growth.
The print will turn on these.
Q1
Will AbbVie achieve an EPS of $3.61 or higher?
This number is crucial as it sets the tone for investor confidence and reflects the company's operational efficiency.
Q2
What guidance will AbbVie provide for future revenue growth?
Future revenue guidance will indicate the company's outlook and ability to sustain growth, which is vital for investor sentiment.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±13.3%
Why consensus could be wrong
The Street may underestimate AbbVie's potential for revenue growth due to its strong pipeline and recent product launches.
Supporting evidence
AbbVie has a history of beating EPS estimates, with an 88% beat rate in recent quarters.
The options market is pricing a larger move than historical averages, indicating potential for a significant reaction.
Recent positive trends in the immunology sector may not be fully reflected in current consensus estimates.
Key risk
If the EPS comes in below $3.54, it could undermine confidence in AbbVie's growth outlook.
Pre-commit to what would confirm each case.
The market is debating AbbVie's ability to maintain its growth trajectory amidst increasing competition and market pressures.
Bull confirmed if
An EPS above $3.61 and revenue exceeding $16.8B would confirm the bull case.
Bear confirmed if
An EPS below $3.54 or revenue below $16.5B would confirm the bear case.
What the market is pricing for the move.
Implied Move
±5.85%
Historical Avg
±3.5%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±5.8% while ABBV has averaged ±3.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
23.2%
Smart-money positioning from the most recent 13F filings.
Institutional
77.34%
of float
Insider
0.11%
of float
Holders
5,237
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
149,488,412 sh · $40.6B
8.46%
-0.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If AbbVie beats expectations, history suggests the stock could rise by around 1.78%, confirming strong operational performance.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further commentary.
Miss
A miss could lead to a decline of about 0.15%, reflecting disappointment in the company's performance.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
2
0 buys·2 sells
Members
2
House only
Est. Notional
$16,002.00–$65,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
115,396,098 sh · $31.3B
6.53%
0.4%
State Street Corporation
82,596,748 sh · $22.4B
4.67%
1.7%
Vanguard Portfolio Management LLC
48,477,996 sh · $13.2B
2.74%
-2.1%
JPMORGAN CHASE & CO
47,862,796 sh · $13.0B
2.71%
-15.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
1 trade
Net selling
Recent Transactions
Traded Sep 14, 2026 · disclosed Sep 18, 2026
$15,001.00–$50,000.00
Traded May 5, 2026 · disclosed Jun 3, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.